Abstract
Microencapsulated pancreatic β-cells have been studied as an ideal system for delivering insulin. However, the clinical applications have not been achieved. We tried multiple excipients/ratios and various methods for producing suitable microcapsules, but success remains limited. A recent study used the tertiary bile acid, taurocholic acid (TCA), to improve the rectal delivery of insulin while another study used TCA to improve the oral delivery of heparin. Thus, in this study, we used TCA in different formulations, using a new microencapsulating method, to study its suitability for β-cell microencapsulation. Using a methodology at set temperature of 37°C, amplitude of 1.5 and a total gelation time of 21 minutes, ten different formulations were examined (with or without TCA) and all formulations showed similar cell viability, which was enhanced by TCA addition. This suggests potential benefits of our microencapsulating parameters and TCA in β-cells microencapsulation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
